Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...

The patent for semaglutide, the drug used in major weight-loss medications like Wegovy and Ozempic has expired. The end of the patent — held by Danish pharmaceutical giant Novo Nordisk — opens the ...

A massive shake-up is underway in India's obesity and diabetes drug market as the patent for Semaglutide—the key ingredient behind blockbuster drugs—expires. This opens the floodgates for over 40 ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Agent workflows make transport a first-order ...

A monthly supply of generic versions of Novo Nordisk’s (NVO) GLP-1 therapy, semaglutide, marketed as Ozempic and Wegovy, could cost less than $3 per person, according to a new study posted this week.

Feb 12 (Reuters) - West Pharmaceutical (WST.N), opens new tab forecast annual profit above Wall Street estimates on Thursday, banking on higher demand for diabetes and obesity treatments that use its ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company plans to use an ...

Every shopper has faced the dilemma: do you grab the cheaper store brand or stick with the familiar name brand? With grocery prices climbing, the choice between saving money and ensuring quality feels ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...